EUDA Health signs LOI to acquire stem cell biotech company

SINGAPORE - EUDA Health Holdings Limited (NASDAQ:EUDA), a healthcare provider with a market capitalization of $54.6 million, announced Wednesday that its wholly-owned subsidiary has signed a Letter of Intent (LOI) to potentially acquire GO POSB Organoids Pte Ltd, a Singapore-based biotechnology company. The announcement comes as EUDA’s stock trades near its 52-week low, having declined over 60% in the past six months.

GO POSB has developed a proprietary platform that reprograms human blood cells into induced pluripotent stem cells (iPSCs), which can differentiate into nearly any cell type in the human body.

According to the press release, the companies are exploring the establishment of an iPSC laboratory and cultivation facility in Shenzhen, China. The facility would serve as a hub to store, expand, and distribute iPSC solutions to hospitals, clinics, and research centers across China, subject to regulatory approvals.

EUDA would provide funding for the facility while collaborating with Singapore’s Agency for Science, Technology and Research (ASTAR) to advance iPSC research, conduct clinical trials, and work on regulatory pathways for therapeutic applications.

The collaboration aims to position EUDA to supply business-to-business iPSC solutions to healthcare providers, including hospitals and regenerative clinics. The company stated the platform could also open opportunities for iPSC-derived product lines for wellness and aesthetics markets.

EUDA Health describes itself as a non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, with a strategic focus on the longevity sector.

The announcement represents a potential expansion of EUDA’s business operations, though the financial terms of the potential acquisition were not disclosed in the company’s statement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.